MARKET

AXDX

AXDX

Accelerate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.15
-0.08
-0.97%
After Hours: 8.15 0 0.00% 16:04 11/25 EST
OPEN
8.08
PREV CLOSE
8.23
HIGH
8.33
LOW
8.01
VOLUME
235.46K
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
4.530
MARKET CAP
464.79M
P/E (TTM)
-5.5922
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Just Reported, And Analysts Assigned A US$15.00 Price Target
The third-quarter results for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) were released last week, making it a good...
Simply Wall St. · 11/07 12:53
Accelerate Diagnostics EPS in-line, beats on revenue
Accelerate Diagnostics (AXDX): Q3 GAAP EPS of -$0.33 in-line.Revenue of $3.59M (+58.1% Y/Y) beats by $0.32M.Press Release
Seekingalpha · 11/05 22:31
Accelerate Diagnostics Q3 EPS $(0.33), Inline, Sales $3.60M Beat $3.27M Estimate
Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.33) per share which met the analyst consensus estimate. This is a 10.81 percent increase over losses of $(0.37) per share from the same period last
Benzinga · 11/05 22:01
Accelerate Diagnostics, Inc. to Host Earnings Call
ACCESSWIRE · 11/05 19:45
Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/29 17:35
Accelerate Diagnostics Announces Virtual Product Demo Day and Schedules Call to Review Third Quarter 2020 Results
PR Newswire · 10/12 14:05
Accelerate Diagnostics Announces New FDA Clearance for Accelerate PhenoTest® Improvements
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the Company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and expand the system's antimicrobial susceptibility testing
PR Newswire · 09/16 14:00
Accelerate Diagnostics Announces New FDA Clearance For Accelerate PhenoTest Improvements
Accelerate Diagnostics Announces New FDA Clearance for Accelerate PhenoTest® Improvements TUCSON, Ariz., Sept. 16, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the
Benzinga · 09/16 13:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXDX. Analyze the recent business situations of Accelerate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXDX stock price target is 15.00 with a high estimate of 20.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 171
Institutional Holdings: 32.87M
% Owned: 57.64%
Shares Outstanding: 57.03M
TypeInstitutionsShares
Increased
28
2.07M
New
24
-369.60K
Decreased
36
2.07M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.24%
Healthcare Equipment & Supplies
-0.25%
Key Executives
Chairman/Independent Director
John Patience
Chief Executive Officer/Chief Operating Officer/Director
John Phillips
Chief Financial Officer
Steve Reichling
Senior Vice President
Ron Price
Other
Nedal Safwat
Independent Director
Thomas Brown
Independent Director
Tom Brown
Independent Director
Roland Diggelmann
Independent Director
Louise Francesconi
Independent Director
Mark Miller
Independent Director
Jack Schuler
Independent Director
Matthew Strobeck
Independent Director
Frank ten Brink
Independent Director
Charles Watts
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AXDX
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Accelerate Diagnostics Inc stock information, including NASDAQ:AXDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXDX stock methods without spending real money on the virtual paper trading platform.